Appeals Court Reverses Infringement Ruling on Shire’s Lialda Patent in Win for Actavis

In a loss for Shire, a three-judge panel for the U.S. Court of Appeals for the Federal Circuit ruled Actavis did not infringe a patent covering the ulcerative colitis drug Lialda, reversing a lower court decision.
Source: Drug Industry Daily